Andy Hsieh
Stock Analyst at William Blair
(2.24)
# 2,785
Out of 5,006 analysts
12
Total ratings
66.67%
Success rate
5.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andy Hsieh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRBP Corbus Pharmaceuticals Holdings | Initiates: Outperform | n/a | $14.83 | - | 1 | Feb 28, 2025 | |
| SKYE Skye Bioscience | Initiates: Outperform | n/a | $4.75 | - | 1 | Feb 28, 2025 | |
| ALT Altimmune | Initiates: Market Perform | n/a | $3.91 | - | 1 | Feb 28, 2025 | |
| TERN Terns Pharmaceuticals | Initiates: Market Perform | n/a | $8.23 | - | 1 | Feb 28, 2025 | |
| GPCR Structure Therapeutics | Initiates: Outperform | n/a | $27.28 | - | 1 | Feb 28, 2025 | |
| BIOA BioAge Labs | Initiates: Market Perform | n/a | $5.61 | - | 1 | Feb 28, 2025 | |
| MRSN Mersana Therapeutics | Initiates: Outperform | n/a | $8.28 | - | 1 | Feb 6, 2025 | |
| PYXS Pyxis Oncology | Downgrades: Market Perform | n/a | $2.57 | - | 1 | Nov 21, 2024 | |
| LNTH Lantheus Holdings | Initiates: Outperform | n/a | $53.83 | - | 1 | Sep 29, 2023 | |
| FGEN FibroGen | Downgrades: Market Perform | n/a | $11.73 | - | 2 | Jun 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.58 | - | 1 | Feb 21, 2023 |
Corbus Pharmaceuticals Holdings
Feb 28, 2025
Initiates: Outperform
Price Target: n/a
Current: $14.83
Upside: -
Skye Bioscience
Feb 28, 2025
Initiates: Outperform
Price Target: n/a
Current: $4.75
Upside: -
Altimmune
Feb 28, 2025
Initiates: Market Perform
Price Target: n/a
Current: $3.91
Upside: -
Terns Pharmaceuticals
Feb 28, 2025
Initiates: Market Perform
Price Target: n/a
Current: $8.23
Upside: -
Structure Therapeutics
Feb 28, 2025
Initiates: Outperform
Price Target: n/a
Current: $27.28
Upside: -
BioAge Labs
Feb 28, 2025
Initiates: Market Perform
Price Target: n/a
Current: $5.61
Upside: -
Mersana Therapeutics
Feb 6, 2025
Initiates: Outperform
Price Target: n/a
Current: $8.28
Upside: -
Pyxis Oncology
Nov 21, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $2.57
Upside: -
Lantheus Holdings
Sep 29, 2023
Initiates: Outperform
Price Target: n/a
Current: $53.83
Upside: -
FibroGen
Jun 26, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $11.73
Upside: -
Feb 21, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $1.58
Upside: -